Educational Workshop on Molecular Imaging - How it Works and What is New?

EIBIR and the ENCITE consortium cordially invite to the educational workshop on molecular imaging with an interesting variety of existing and new methods. The workshop will take place in Prague, in May 7-8, 2009.

Preliminary Programme

Thursday, May 7, 2009

13:00 - 13:15 Welcome

13:15 - 15:00 Session 1, Novel Imaging Technologies
15:15 - 16:45 Session 2, Novel Imaging Reporters Probes

Friday, May 8, 2009

09:00 - 10:30 Session 3, Novel T ools for Cell Labelling
10:45 - 12:30 Session 4, Preclinical Validation
13:30 – 15:00 Session 5, Translation towards Clinical Applications

Physicists, technicians, biologists, chemists and other professionals with an interest in the field of molecular imaging are cordially welcome to attend this workshop.

Participation is free of charge. Pre-registration is mandatory until April 20, 2009.

Please click here for the invitation and the programme.

For further information, please visit:
http://www.eibir.org

About The European Institute for Biomedical Imaging Research (EIBIR) The European Institute for Biomedical Imaging Research (EIBIR) is a non-profit limited liability company that was founded in 2006 by the European Society of Radiology (ESR), dedicated to the co-ordination of research.

EIBIR has the aim of co-ordinating and supporting the development of biomedical imaging technologies and the dissemination of knowledge with the ultimate goal of improving diagnosis, treatment and prevention of disease.

The platform supports networking activities in research and is key to spreading good practice, promoting common initiatives and interoperability in the field of biomedical imaging research.

This will generate critical mass and help coordinate research into new instrumentation, new methods, concepts and technologies.

Most Popular Now

Making Cancer Vaccines More Personal

In a new study, University of Arizona researchers created a model for cutaneous squamous cell carcinoma, a type of skin cancer, and identified two mutated tumor proteins, or neoantigens, that...